Nasus Pharma Ltd. (NSRX:NYSEMKT) closed at $3.49 on October 23, 2026, up 8.05% on the day. The stock trades 63.3% below its 52-week high of $9.50 and 76.3% above its 52-week low of $1.98. Over the past year, it lost 55.8%. Nasus Pharma Ltd. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, NSRX closed higher on 107 days (42%). Its best day was April 20, 2026 (+27.68%) and its worst was March 16, 2026 (-38.00%). The stock moved 10% or more in a single session 25 times. It opened at least 5% above the previous day's high 8 times.
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions. Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active powder-based intranasal technology, or PBI, specialized products. To help achieve this we are focused on developing NS002, an intranasal powder Epinephrine nasal spray for the treatment of type 1 severe allergies and anaphylaxis, or Intranasal Epinephrine, and we also have been developing NS001, an intranasal Naloxone powder nasal spray for the treatment of opioid overdose, or Intranasal Naloxone. We currently have no FDA approved products. Our products have been tested on relatively small patient populations thus far.
Find more stocks like NSRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.